Go Pro
→ Trump’s “new Petrodollar” exposed (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.71
+0.8%		$3.49
$1.90
▼
$8.21
$801.87M2.143.05 million shs2.30 million shs
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
▼
$18.00
$834.46MN/A11,851 shs39 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.30
+2.8%		$7.26
$3.86
▼
$9.31
$597.76M1.421.09 million shs684,831 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-1.08%+7.60%+10.84%+22.67%+73.58%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
-0.11%+1.91%+47.88%+35.68%+22.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.71
+0.8%		$3.49
$1.90
▼
$8.21
$801.87M2.143.05 million shs2.30 million shs
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
▼
$18.00
$834.46MN/A11,851 shs39 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.30
+2.8%		$7.26
$3.86
▼
$9.31
$597.76M1.421.09 million shs684,831 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-1.08%+7.60%+10.84%+22.67%+73.58%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
-0.11%+1.91%+47.88%+35.68%+22.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.83
Moderate Buy$11.90220.75% Upside
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
2.50
Moderate Buy$14.5055.91% Upside

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, and CXRXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
8/19/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$12.00 ➝ $11.00
8/10/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $14.00
7/21/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/17/2026
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
6/16/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
6/15/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M10.61N/AN/A$1.39 per share2.67
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
Evolus, Inc. stock logo
EOLS
Evolus
$297.18M2.07N/AN/A($0.47) per share-19.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.50N/AN/AN/A-435.21%-38.46%-30.33%11/5/2026 (Estimated)
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/AN/A-15.31%N/A-4.38%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$51.64M-$0.52N/A116.25N/A-10.85%N/A-13.00%11/4/2026 (Estimated)

Latest EOLS, CTMX, and CXRXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.0771-$0.09-$0.0129-$0.09$12.39 million$1.42 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
9.36
9.36
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
Evolus, Inc. stock logo
EOLS
Evolus
N/A
1.70
1.28

Institutional Ownership

CompanyInstitutional Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Evolus, Inc. stock logo
EOLS
Evolus
90.69%

Insider Ownership

CompanyInsider Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.80%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Evolus, Inc. stock logo
EOLS
Evolus
5.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170217.90 million209.62 millionOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
Evolus, Inc. stock logo
EOLS
Evolus
17066.05 million62.75 millionOptionable

Recent News About These Companies

Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 105,108 Shares of Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-evolus-nasdaq-eols-insider-sells-105108-shares-of-stock-2026-09-04/
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
September 2 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-investment-in-evolus-inc-eols-2026-09-02/
Evolus (NASDAQ:EOLS) Reaches New 12-Month High - Should You Buy?
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-evolus-nasdaq-eols-reaches-new-12-month-high-should-you-buy-2026-08-31/
Nantahala Capital Management LLC Takes $38.88 Million Position in Evolus, Inc. $EOLS
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nantahala-capital-management-llc-takes-3888-million-position-in-evolus-inc-eols-2026-08-29/
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Brokerages
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30990483
625,000 Shares in Evolus, Inc. $EOLS Purchased by AWH Capital L.P.
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-625000-shares-in-evolus-inc-eols-purchased-by-awh-capital-lp-2026-08-28/
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
August 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980998/wall-street-analysts-think-evolus-eols-could-surge-77-68-read-this-before-placing-a-bet?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2980998
454,930 Shares in Evolus, Inc. $EOLS Acquired by Deutsche Bank AG
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-454930-shares-in-evolus-inc-eols-acquired-by-deutsche-bank-ag-2026-08-27/
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985331
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-evolus-eols-buy-rating-reaffirmed-at-hc-wainwright-2026-08-25/
Evolus (NASDAQ:EOLS) Reaches New 1-Year High - What's Next?
August 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30982073
Evolus (NASDAQ:EOLS) Reaches New 52-Week High - Time to Buy?
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-evolus-nasdaq-eols-reaches-new-52-week-high-time-to-buy-2026-08-25/
Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of "Moderate Buy" from Analysts
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/evolus-inc-nasdaqeols-receives-average-recommendation-of-moderate-buy-from-analysts-2026-08-24/
Evolus (NASDAQ:EOLS) Reaches New 12-Month High - Time to Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/evolus-nasdaqeols-reaches-new-12-month-high-time-to-buy-2026-08-19/
1,289,888 Shares in Evolus, Inc. $EOLS Purchased by Rice Hall James & Associates LLC
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1289888-shares-in-evolus-inc-eols-purchased-by-rice-hall-james-associates-llc-2026-08-18/
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-lowers-stake-in-evolus-inc-eols-2026-08-13/
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-grows-stock-holdings-in-evolus-inc-eols-2026-08-12/
Evolus: The Injectable Platform Is Becoming The Real Moat
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934641-evolus-the-injectable-platform-is-becoming-the-real-moat
Evolus (NASDAQ:EOLS) Reaches New 1-Year High - Here's What Happened
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/evolus-nasdaqeols-reaches-new-1-year-high-heres-what-happened-2026-08-11/
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
August 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972728/wall-street-analysts-believe-evolus-eols-could-rally-106-08-here-s-is-how-to-trade?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2972728
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/evolus-nasdaqeols-rating-increased-to-buy-at-wall-street-zen-2026-08-08/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.71 +0.03 (+0.82%)
As of 04:00 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.30 +0.25 (+2.76%)
As of 04:00 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas